摘要
肌萎缩侧索硬化是一种罕见致死性神经系统疾病,收录于2018国家卫生健康委员会等5部委联合制定的《第一批罕见病目录》中。依达拉奉是一种自由基清除剂,2017年美国FDA批准了依达拉奉治疗肌萎缩侧索硬化新适应证并作为孤儿药物在美国上市。本文从依达拉奉的药动学、毒理学研究、药理作用和作用机制4个方面总结了依达拉奉与肌萎缩侧索硬化疾病相关的临床前研究进展。
Amyotrophic lateral sclerosis(ALS) is a rare progressive nervous system disease that affects nerve cells in brain and spinal cord,causing loss of muscle control.It was included in the"First Catalogue of Rare Diseases"formulated by five ministries and commissions such as National Health Commission in 2018.Edaravone is a free radical scavenger and its intravenous injection was approved as an orphan drug by the FDA to treat people with amyotrophic lateral sclerosis in the United States in May 2017.This article summarized the preclinical research progress of edaravone related to ALS,including pharmacokinetics,toxicology,pharmacology and mechanism of action.
作者
李天磊
韩遵圣
张驰
戚燕
严婷
吴松
LI Tian-lei;HAN Zun-sheng;ZHANG Chi;QI Yan;YAN Ting;WU Song(State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第23期2695-2699,共5页
Chinese Journal of New Drugs
基金
国家自然科学基金项目(81703364)
中国医学科学院医学与健康科技创新工程重大协同创新项目(2017-I2M-1-011)。
关键词
依达拉奉
肌萎缩侧索硬化
作用机制
药理作用
毒理学
药动学
edaravone
amyotrophic lateral sclerosis
mechanism of action
pharmacology
nonclinical toxicology
pharmacokinetics
